EZH2 anticorps (AA 410-440)

N° du produit ABIN6244310

Cet anticorps Lapin Polyclonal détecte spécifiquement EZH2 dans WB et IHC (p). Il présente une réactivité envers Humain et Souris et a été mentionné dans 4+ publications.

Aperçu rapide pour EZH2 anticorps (AA 410-440) (ABIN6244310)

Antigène: EZH2 (Enhancer of Zeste Homolog 2 (EZH2))

Reactivité: Humain, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp EZH2 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: RB2921

Détail du produit anti-EZH2 anticorps

Épitope: AA 410-440

Homologie: X, Pr

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogène: This EZH2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from 410-440aa of human EZH2.

Isotype: IgG

Information d'application

Indications d'application: WB: 1:1000. WB: 1:1000. IHC-P: 1:50~100. IHC-P: 1:50~100

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Date de péremption: 6 months

Références pour anticorps anti-EZH2 (ABIN6244310)

Pan, Wang, Zhu, Xing, Cui, Li, Yu, Wang, Zhu, Ye, Wu, Wang, Lu: "STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer." dans: Molecular cancer, Vol. 15, Issue 1, pp. 79, (2017) (PubMed).

Lin, Zheng, Tu, Wang, Liu, Lu, Xu, Yuan: "MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2." dans: Human pathology, Vol. 46, Issue 7, pp. 971-80, (2015) (PubMed).

Eskander, Ji, Huynh, Wardeh, Randall, Hoang: "Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines." dans: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 23, Issue 6, pp. 997-1005, (2014) (PubMed).

Zhou, Flesken-Nikitin, Corney, Wang, Goodrich, Roy-Burman, Nikitin: "Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer." dans: Cancer research, Vol. 66, Issue 16, pp. 7889-98, (2007) (PubMed).

Détails sur EZH2

Antigène: EZH2 (Enhancer of Zeste Homolog 2 (EZH2))

Autre désignation: EZH2

Sujet: EZH2, SUZ12, and EED form a complex that methylates nucleosomal histone H3 at Lys27. EZH2 contains a SET domain, a signature motif for all known histone lysine methyltransferases except the H3-K79 methyltransferase DOT1, and is therefore likely to be the catalytic subunit. Consequently, EZH2 is thought to regulate gene expression by controlling chromatin structure. Several lines of evidence suggested a critical role for the EZH2 protein during normal and perturbed development of the hematopoietic and central nervous systems. The EZH2 protein has been shown to associate with the VAV1 protooncoprotein and with the XNP protein, the product of a gene associated with mental retardation. Additionally, due to mapping of EZH2 to the 7q35-q36 chromosomal region associated with myeloid disorders, this protein is suggested to participate in the genetic events triggering myeloid leukemia.

Poids moléculaire: 85363

NCBI Accession: NP_001190176, NP_001190177, NP_001190178, NP_004447, NP_694543

UniProt: Q15910

Pathways: Retinoic Acid Receptor Signaling Pathway, Regulation of Muscle Cell Differentiation